GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Prescient Therapeutics PTX.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.06

+3.70%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Prescient Therapeutics — daily ASX:PTX

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Prescient Therapeutics on TradingView ↗
Market value
A$45.1m
Last close × shares
Volume
260.6k
Shares, 9 Nov 2026

About Prescient Therapeutics

Its shares trade on ASX under the ticker PTX.AX. It has been listed since 12 June 2013. In the fiscal year to 30 June 2025, it reported revenue of A$4.4m and a net loss of A$7.3m. At that date it held total assets of A$14.6m and shareholders' equity of A$11.4m.

Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2013-06-12. The firm is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The firm is engaged in developing compounds to treat a range of solid and hematological cancers. The company is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.

Figures and description from our data supplier, not checked against the company's own report.

More about Prescient Therapeutics →

Latest on Prescient Therapeutics

Our reporting

We have not reported on Prescient Therapeutics yet.

Next results

19 Feb 2027

Due on 19 Feb 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Prescient Therapeutics's ticker?

Prescient Therapeutics trades as PTX.AX on ASX, under ISIN AU000000PTX3.

What was Prescient Therapeutics's last closing price?

0.06 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Prescient Therapeutics next report results?

Results are expected on 19 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.